Nevertheless, owing to the lack of viable LOX-deficient mice (Maki et al., 2002; Hornstra et al., 2003), this inhibitor has been extensively used in short-term in vivo studies to support the involvement of lysyl oxidases in multiple biological processes, including tumour progression and metastasis (Levental et al., 2009; Erler et al., 2006), pulmonary arterial hypertension (Nave et al., 2014) and arterial stiffening (Kothapalli et al., 2012). Here, LOX is linked to pulmonary arterial hypertension.